Xeris Biopharma Holdings, Inc. at XP-8121 Program Overview Transcript
Hello, everyone. Thank you for joining us, and welcome to Xeris Biopharma XP-8121 Program Overview. (Operator Instructions) I will now hand the conference over to Allison Wey, Senior Vice President of Investor Relations. Allison, please go ahead.
Good morning, everyone, and welcome. I'm Allison Wey, Senior Vice President of Investor Relations. On behalf of the entire Xeris team, thank you for joining us today for XP-8121's program overview.
We will start the presentation today with John Shannon, Chairman and Chief Executive Officer of Xeris, who will set the stage for everything you're about to hear, including why we believe our candidate drug product, XP-8121, a once-weekly subcutaneous injection of levothyroxine for the treatment of hypothyroidism, has the potential to be a blockbuster.
From there, you'll hear from Dr. David Robertson, a leading endocrinologist and an investigator in our Phase 3 registrational study. Dr.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
